
Theralase raises C$4.76M to fund cancer drug trials and toxicology studies
Theralase Technologies Inc. completed a private placement raising C$4.76 million to support its Phase II bladder cancer clinical trial and begin toxicology studies for its drug Rutherrin®. The financing includes brokered and non-brokered offerings wi...


